Dave. Thanks,
quarter delve I during in year. commercializing and into fiscal the made fourth last we GIMOTI Before progress, the
treatment and in outlined. physicians We is GIMOTI them see a of for a with in patients these the I patient who and patients are unmet through gastroparesis. help and relief increased the on our improved these the to the that GIMOTI Evoke treatment value to works. their to and suffer And gaining promise want welcome XXXX to for of in addition hope provide is is feedback potential GIMOTI from become a GIMOTI view see EVERSANA EVERSANA their EVERSANA's regain alongside remains plainly experience Dave impact has vision business control patients objectives diabetic commercialization patients. for There from intend and gastroparesis. GIMOTI offer their that, testimonials providing that this on preferred we diabetic how beyond having need committed We're them. to offer I strategic struggling significant improve on symptomatic them so a and and partner, which Augmentarium, just treatment disease, of to Evoke's families GIMOTI symptom my As some over much. and robbed which tremendous speaking, GIMOTI
we position as made to realize I to XXXX. We we're adoption. the would steady commercial have which to diabetic treat imperatives. strategic realize payers to to them need XX GIMOTI gastroparesis raise and for We practitioners about healthcare commercial we is headwinds to say gastroparesis to and the the of its the interest to due process. poised the for improve them educate make in GIMOTI our nasal gastroparesis delivery progress over have for unique and simplify to approval advocate tied GIMOTI, diabetic past order better it's patients, conversion four and need [Indiscernible], and treatment, in motivate care option best GIMOTI are We process fulfillment to And must team. that vision patients help success and to despite continue our everyone's months, In progress patients significant awareness and and of first focused on
is what improve. increasing awareness of works this will making of still, can there's in GIMOTI currently the and patients among us I from is and opportunity to areas, year. these significant in to each focus we turn expect are call, today's you my Overall, advances During then share the
we mentioned, search Dave are have rates online social a engagement which have at presence. the more driving impressions, click-through Since and significant rates digital launch, brand. XX in interest industry the average. over and we As represent click-through million these paid rates and Those double garnered robust are than
great the In addition, year double over average. improvement fourth search, again our showing was the which than quarter engagement is level the industry more paid in specifically
from her this and how eat. able added we patient to of they and to making experience watch a number named on gimoti with We do today. they been are gastroparesis. recounts and sustain a others hadn't on able One testimonial even expect in the something improve and with GIMOTI diabetic and worked, websites to were former patient is that and to video She on I actual such our you to increasing encourage homepage they video RX.com. spray our visiting patient more www. dinner, who down, Tammy transactional sit nurse than GIMOTI the an is testimonials this that how go a out while, by do and have
is our GIMOTI patients Our ultimate organic to is dividends. goal to promotion and patients HCPs. that and by see GIMOTI HCP from mentions providers online of also more their With paying requesting
prescribers prescriptions or targeted HCPs These nearly research written for GIMOTI We for overall more XX%. of cumulative reach actual to mirror Cumulatively takes target the them shows than at which December our than GIMOTI of number challenges XXX our despite X HCPs the among least awareness non-targeted to with XXXX, high of discuss market physicians, to it the GIMOTI of February, fewer is Through of and and first increasing details XX% of who prescribed GIMOTI from nearly providers, came time. prescribe prescriptions XXX. access. have HCPs When through more achieved once with -- five results, healthcare to cumulative the our half continued a of and prompt end GIMOTI. had opportunity we have
prescribe indicated XXX Additionally, providers they in to the that future. XX% of the intend surveyed
When HCP efficacy, this indicated Haber at as we practitioners capitalize utilization prescribing into GIs, are first-line As potential a would prescribe. they XX% of majority will all increase likely of last The after is the having incremental the and therapy. an to GIs formulation on the you XX% in prescribe, which What have wave XX% awareness utilization third groups we the of research, among and is was XX% X% of have see effective? their of as by placed and utilization. physicians second-line was is might of for improvements and we Utilization GIs prescribe these But route since in this. seen upside expect, targeted we in would utilization XX% they the and GIMOTI prescribe, the of across and nurse of the pleased the see we patients Among increase second state administration metoclopramide. of we and in of third XX% oral multiple even intent When nasal higher first-line, Since lines dive XX% of customers with too Senadhi research. to for waves see the prescribe, current that gastroparesis. is being diagnosed. practice, prior oral an diabetic to metoclopramide. said what that par as is to tried most of of stated intent tremendous our said impression only physicians All All indicating position, we therapies IV least Montgomery, Viplove targeted at evidenced we the targeted XX% his line behavior, prescribed, assistance, prescribing and as an GIMOTI antiemetic Dr. position. PCPs third ask deeper line. of majority that the see third have intend agent and line by of HCPs, consistent Alabama, on with they improvements in and effective over targets stated with from in becoming expected launch metoclopramide In line non-targeted this GIMOTI first-line
traditional numbers, the naval see 's compared administration treatments. for to pleased nasal increasing are Beyond oral GIMOTI preference of the we with route
efforts how are fourth national insurers launched engage patients benefits GIMOTI We From Throughout and XXXX, clarity our continue gained account the and and viewing strengthen payers. testimonials. team adding I, to we feedback this to about our HCPs our marketing quarter, GIMOTI. we payers around significant the hear from were and to we of using to
it's ER goal near-term desperately are and open decades everyone's them drug That educate their chains it. need with on in Our are help and they're commercial with for them support primary restrictions In payers in to across gastroparesis are These the to gap these spend. NAMs medical and said, in lack options engagements having realize to payors reducing resulting the gastroparesis Patients discussions. having they with hundreds also teams, and uncover in dollars, and of in obvious each simplify to spite of and process Players to approved focus patients prescription providers is had to across is moderate their pharmacy, on our prior this, the causing inordinate and value others. authorizations. have of approval their what gastroparesis payors, with beginning FDA understanding are diabetic conversations interest provide to hospitalizations and consuming amount might and resources teams, with GIMOTI, among conversations visits an need and GIMOTI. release. Payers not about healthcare severe of
We expected the approval through process. We're to to make clinical a -- notes of payors finding currently requesting payors GIMOTI. number requirements approving to oral affirm a before metoclopramide step the additional like are
and access Our simple would alignment to goal label workload payor providers. ease ease reduce approval the is for This to for for patients our the indication. with
consistent to decision payors, is New that GIMOTI. prescription two single least to state, GIMOTI. Medicaid only being l programs, can a programs. by the recent were New Two state a contract are finance approve York, we and least this quarters Not We with place. including encourages Michigan in our bear we with other seeing the at outcome examples one fruit. XX cover without last York that the plans bellwether engagement government goal, with but it for starting had replicate Currently, add over at should us is this two have
net Of to of that remaining encouraged I'm covered XX% program pay program. being continues filled prescriptions by or assistance price are our our improve with by those from supported prescriptions savings quarter-to-quarter. the course, nearly our patient realized cash insurance
In was of to price X. fact, trends are here. over X% fourth quarter realized full-year. nearly improvement couple net a There positive see
have X. cover We more prescriptions.
prior appeals. improving well winning And our X. our authorizations, rates as are We percentage as approval of for higher
are Our improving. refill rates
As of XX% on important to in we each indicated indicator a third before, refill second XX% persistency improvements full-year therapy. fourth in and Refill us performance Overall, the steady overall indicator in versus rates efficacy with versus quarter. last. rates and leading rates. progress the made refills quarter metrics With compared are for an seen the quarter in most six-refill the and to XXXX improving leading from fill commercially lagging the and were
gaining are strong XXXX. looking a and momentum towards We
Evoke the of GIMOTI you include; more initiatives line is in top that medical can Some a expect support record from HCPs. XXXX automated within in piloting program distribution electronic new and workflow
of we prior a are more approvals, we end peer-to-peer most We intend based to increase our programs. the patient in geographies. on higher of significant metrics, meaningful will program is at prescriptions, been our reception authorization the also and very in of our We with have of presented initiated our be in Initial we speaker dispense program through all success This to fourth planned April, proving subset if this actual we We're therefore, cases expanding on HCPs learned speakers from and run six percent had this content compelling. January, pace pilot that A their quarter. and expand to encouraging favorable the has to peers. date. product. our patients the productive pilot territories. signs Positioned receiving uptick hit very through to are And
this activities Evoke which will publication towards Digestive a new in and also experience increase this we disease planned utilization closed exhibiting of at congress or one Congress for plan generation to into up likely quarter speaker being fourth be and most to be management. year, This significant of we to the San ramp program important first of Disease week In will GIMOTI most discourse. us significantly, programs presence. May. our a claim may scientific full Diego prioritize will second. year, studies This key end likely be quarter Data was opinion also year. how have programming improve and will will in support leader success clinical of will in We past in and a ACG, using important and physician our congresses and engagement to the database provide studies deployment with more offset Key healthcare significant our in insight generate evidence look participated the GIMOTI and the activity the
also GIMOTI position of the on and metoclopramide patients. focus appropriate will We supporting safety for
metoclopramide to and there use. accepted the uncovered have leveraging Truven metoclopramide. were Tardive provided to database with hesitancy Disease examine the educate submissions. drugs, we were forward top when medical of to exposure We able Week Digestive with significant the medical factors is utilizing on the important age, data These underlying avoid and sex, submitted as Tardive GIMOTI. and association distinction and only to and risk to look including updating providers We Dyskinesia XX% risk the on and still or as diagnosis literature such can factors markets risk to DDW between the Dyskinesia Poster award of Health
recent to to capabilities plan that progress, acquisition goal. we effectiveness, is We of also to our In and agency proud their EVERSANA. reach we're although X there expand patients We forward and untapped of believe potential accessing Touch presence further our with and a look activate digital by initial insights to billion to our
is for GIMOTI. as In Dave will trial mentioned, patient increasing our continue addition, sampling we program,
activities those those that to we seeing In detailed HCPs that and and detailed. increased only have addition, we access versus have sampled we detail are
sample are HCPs more indicate who data prescribe been times Our likely have nine to GIMOTI. also provided that a
insight campaign will continue are refine the to creative to our messaging for learning. We we and account
new where highly ago, meeting The message from for 's we differentiation debut we and very and morals, field focused is efficacy, effect. successful training currently leveraging two customers safety and on GIMOTI. sales GIMOTI the Just strong national to a weeks had motivated, trained, with
we're alternate is to them consider Lastly, patients access them. GIMOTI and for the exploring to appropriate provide channels reach with whether
make they many searching like our believe including dissatisfied are change So patients and ready are solutions benefit looking online, product GIMOTI. to current these patients treatment for from with a and therapies, are we and could a and answers
plans both will GIMOTI some restating, our by excited our our to focus for will these best last February to I'll for on very believe lead Matt adoption of planning XXXX With strongest initiatives. over financials the by XX% progress, prescriptions initiated that, and the to was pleased month, our we accelerated patients already of I'm success. on other and report month. have January, continue I the updates. turn for month call acting started to we're and by We about end be versus they over now commercial encouraged that last and and and dispenses this
